Organogenesis Advances Promising ReNu Therapy in Phase 3 Study A Potential Game-Changer in Pain Management,

Organogenesis Provides Update on Second Phase 3 ReNu® Study – Ortho Spine News

Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint Statistically significant maintenance of function (p

Organogenesis Advances Promising ReNu Therapy in Phase 3 Study A Potential Game-Changer in Pain Management,

Organogenesis Provides Promising Update on Second Phase 3 ReNu Study in Innovative Pain Management In a recent press release, Organogenesis Holdings Inc. has provided an important update regarding its ongoing Phase 3 clinical trial for ReNu, an innovative pain management therapy that could potentially transform the way we approach chronic pain. This press release highlights the company's commitment to delivering effective solutions for patients …